Foghorn Therapeutics Inc. FHTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -61.48%
- 1 year
- -51.74%
- Open
- 2.08
- Prev close
- 2.09
- Mkt cap
- 123.52M
- Vol
- 555.61K
- Avg vol
- 721.87K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.01
- High
- 2.09
- Forward P/E
- -3.12
- Beta
- 3.15
- Short ratio
- 7.62
- Inst. own
- 72.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.50
- 200-d avg
- 6.85
- 1y target
- 12.00
News
2 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are…
3 days ago zacks.com
Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?
Foghorn Therapeutics (FHTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are…
4 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock…
-
4 weeks ago benzinga.com
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
-
4 weeks ago benzinga.com
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.
4 weeks ago benzinga.com
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
4 weeks ago benzinga.com
This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
-
4 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.
1 month ago benzinga.com
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Corteva plunged 84%.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
1 month ago benzinga.com
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics stock drops as Eli Lilly ends partnership, prompting a 40% workforce cut to extend cash runway into 2029 while pivoting pipeline.
1 month ago benzinga.com
Dow Falls Over 200 Points; Micron Earnings Top Views
U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estimates, and European markets declined.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
-
1 month ago benzinga.com
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion…